Ozempic, Wegovy May Curb Cravings for Alcohol, Nicotine, Study Suggests

New obesity and diabetes medications like Ozempic and Wegovy, which mimic the GLP-1 hormone, are showing potential beyond weight loss. These drugs, initially developed to manage blood sugar, also increase feelings of fullness. However, emerging research indicates they may significantly impact the brain's reward system, influencing cravings for substances beyond food.

Studies suggest that GLP-1 agonists can reduce alcohol consumption. Preclinical research in animals further indicates a potential to curb the use of hard drugs like cocaine and amphetamines, as well as nicotine. This suggests a broader therapeutic application for these medications, potentially treating addiction alongside obesity.

Scientists are exploring the precise mechanisms behind these effects. While the brain's dopamine-producing reward pathways, such as the ventral tegmental area (VTA) and nucleus accumbens (NAc), have been studied for decades, they show limited GLP-1 receptor density. Researchers are now examining other brain regions to fully understand how these drugs regulate consumption and cravings.